Allergan Plc (AGN) Return on Equity ROE from the first quarter 2020 to first quarter 2019 and annually, average high and low, overall ranking from Mar 31 2020 to Mar 31 2019 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Allergan plc  (NYSE: AGN)

Allergan Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Allergan Plc in the first quarter 2020?
Allergan Plc had a negative return on equity (ROE) of -4.23%, due to the net loss of $-2 billion, during the twelve months ending in the first quarter 2020.

Within the Major Pharmaceutical Preparations industry 62 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2019 from 0 to 2652.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2020)
I. Quarter		 (Dec 31 2019)
IV. Quarter		 (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter
Y / Y Equity Change -5.75 % -10.65 % -17.05 % -16.23 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -2,479 -5,265 -9,244 -8,494 -7,210
Return On Equity (TTM) -4.23 % -8.85 % -15.1 % -13.23 % -10.74 %
AGN's Total Ranking # 2652 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 58,022 58,196 58,498 59,696 61,560
Seq. Equity Change -0.3 % -0.52 % -2.01 % -3.03 % -5.48 %
Seq. Net Income Change - - - - -

Back to AGN Management Effectiveness >> AGN's 5 Years Annual ROE >> Compare AGN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 63
Sector # 212
Overall # 2652

Return On Equity Statistics
High Average Low
32.13 %
8.85 %
-15.1 %
(Sep. 30, 2005)   (Sep 30 2019)





AGN Annual Return On Equity (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015
Total Equity in Millions 58,196 65,131 73,837 76,201 76,589
Y / Y Equity Change -10.65 % -11.79 % -3.1 % -0.51 % 887.87 %
Net Income in Millions -5,265 -5,086 -4,119 14,980 3,919
Y / Y Net Income Change - - - 282.19 % 157.14 %
Return On Equity -9.05 % -7.81 % -5.58 % 19.66 % 5.12 %

Back to AGN Management Effectiveness >> AGN's 5 Years Annual ROE >> Compare AGN ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AGN's' Return on Equity at Yahoo Finance
AGN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AGN's Competitors
Subscribers only: Roe for Allergan Plc's Suppliers
Subscribers only: Return On Equity for AGN's Customers




Companies with similar Return On Equity at Mar 31 2020, within Healthcare Sector ROE

Date modified: 2026-09-26T07:20:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.